Navigation Links
Avista Capital Partners Agrees to Sell BioReliance to Sigma-Aldrich Corporation
Date:1/9/2012

ROCKVILLE, Md., Jan. 9, 2012 /PRNewswire/ -- BioReliance, a leading provider of global biopharmaceutical testing services, announced today that it has agreed to be acquired by Sigma-Aldrich Corporation (NASDAQ: SIAL).  Avista Capital Partners, the majority owner of BioReliance Holdings, Inc., agreed to sell the company for $350 million in cash.  The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012.

BioReliance provides critical services that include biologics testing, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science clients worldwide.  BioReliance's service offering helps facilitate drug development, manufacturing and commercialization activities.  The Company's ability to develop and execute global testing protocols in compliance with various regulatory standards enables BioReliance's clients to register products with regulatory agencies worldwide.

Sigma-Aldrich is a leading Life Science and High Technology company.  Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing.

Commenting on the transaction, BioReliance's President and CEO Charles Harwood stated, "The acquisition of BioReliance by Sigma-Aldrich creates one of the broadest product and service offerings for the development and manufacture of biological drugs.  In addition, BioReliance's Specialized Toxicology and Animal Health Services segments are complementary to other Sigma-Aldrich product and technology areas."

Avista Capital Partners acquired BioReliance in 2007.  With regards to the acquisition of BioReliance by Sigma-Aldrich, Avista Partner and President David Burgstahler commented, "BioReliance is a world-class organization led by an outstanding team of seasoned life sciences professionals that has demonstrated success through impressive growth, scientific innovation and exceptional customer service.  Avista is committed to work with Sigma-Aldrich to ensure the successful transition of BioReliance and believes that the addition of BioReliance's capabilities and service portfolio will allow Sigma-Aldrich to significantly enhance value to its clients and stakeholders."

J.P. Morgan Securities LLC acted as financial advisor and Weil, Gotshal & Manges LLP served as legal advisor to BioReliance for this transaction.

About BioRelianceBioReliance Corporation is a leading provider of cost-effective contract services to the pharmaceutical and biopharmaceutical industries, offering more than 1,000 tests or services related to biologic testing, specialized toxicology and animal health services.  Founded in 1947, BioReliance is headquartered in Rockville, Maryland, with laboratory operations in Rockville and Scotland and offices in Tokyo, Japan, and Bangalore, India. The Company employs more than 650 people globally.  For more information, visit www.bioreliance.com.

About Avista Capital PartnersAvista Capital Partners is a leading private equity firm with over $4 billion under management with offices in New York, Houston, and London. Founded in 2005, Avista's strategy is to make controlling or influential minority investments in growth-oriented energy, healthcare, media, industrial and consumer businesses. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses. For more information visit: www.avistacap.com.Contact: For BioReliance:For Avista Capital Partners: Mike GarrettJames DavidDirector, Market DevelopmentKekst and CompanyBioReliance Corporation+1 (212) 521-4825+1 (301) 738-1000

 


'/>"/>

SOURCE BioReliance Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive
2. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
3. Sagard Capital Increases Ownership in GP Strategies by 350,000 Shares in a Private Transaction with Bedford Oak Partners, L.P.
4. Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years
5. IsZo Capital Writes to Taro Pharmaceutical Board Commenting on Management Proposals for 2011 Annual Shareholder Meeting; Reflecting on Sun Pharmas Response to Similar 2009 Proposals
6. IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders Meeting
7. Physicians Capital Investments Announces Relocation of its Corporate Headquarters to Dallas, TX
8. HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO
9. WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering
10. WestPark Capital Announces $2.6 Million IsoRay Offering
11. Physicians Capital Investments Announces Pedro Vergne-Marini, MD Named to Beckers ASC Review "350 People in the ASC Industry to Know"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  SI-BONE, Inc., a medical device company ... ("iFuse"), a minimally invasive surgical (MIS) device indicated for fusion for ... Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited ... their Miami dental office. Beginning in January, Miami Dental Specialists will offer the non-metal ... are the first office to be chosen by the dental implant manufacturer, Straumann, to ...
(Date:2/12/2016)... ... 12, 2016 , ... Nearly every health website and vision ... articles generally list between five and 15 foods that should be consumed regularly ... of these lists and believes that nutritious eye healthy foods are extremely important, ...
(Date:2/12/2016)... Colo. (PRWEB) , ... February 12, 2016 , ... A ... the past 35 years. A president has access to health and wellness resources most ... the free world, no single individual has a schedule as frenetic as the U.S. ...
(Date:2/12/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... the real facts surrounding all those Bible stories. For generations families have gathered to ... Yisrayl says there is more to these than just mere “stories”. , The ...
(Date:2/12/2016)... ... ... Dignity Health named Dr. Scott Bingham the Facility Medical Director of the ... licensed under Dignity Health Arizona General Hospital , which opened last year in ... our new freestanding emergency room delivers the highest quality care to Mesa and the ...
Breaking Medicine News(10 mins):